Dear Readers,
This issue showcases recent presentations and publications, including those from the ASCO 2025 meeting. These highlight the remarkable progress in cholangiocarcinoma (CCA) research and treatment. Zanidatamab has shown activity in HER2-amplified tumors, including biliary tract cancers (BTC). Zanidatamab-hrii is an antibody–drug conjugate being developed with potentially greater potency and broader antitumor activity. Kim et al, from Mayo Clinic, reported that zanidatamab-hrii significantly extended both overall survival and progression-free survival compared with second-line chemotherapy.
Three years after approval of durvalumab and pembrolizumab, prognostic and predictive biomarkers for immune checkpoint inhibitors continue to be explored in BTC. Shibuki et al studied Japan/US cohorts and provided new insights into genomic profiles that include TP53 mutations as prognostic markers that may also predict response to immune checkpoint inhibitors. In addition, novel checkpoint inhibitors continue to be investigated. Zhou et al reported rilvegostomig, a bispecific antibody (programmed death-ligand 1 and TIGIT), in combination with chemotherapy as a promising new frontline option in a multicenter, phase 2 trial. Zhou and colleagues studied over 1000 veterans with CCA and confirmed real-world efficacy of ivosidenib in IDH1-mutated CCA. Early detection of BTC remains elusive. Wang et al advanced early-detection efforts with cell-free DNA fragmentomics and machine learning, offering hope for noninvasive screening. Their work demonstrated significant results compared with non-BTC controls. Together, these studies reflect the rapid evolution of targeted therapies, immunotherapy, and early-detection strategies in CCA.
We warmly welcome you to continue these conversations at the CCA Summit, October 2-3 in Scottsdale, AZ, where innovation, collaboration, and hope will take center stage.
Warm Regards,
Milind Javle MD
To sign up for our newsletter or print publications, please enter your contact information below.
